Biosimilars have the potential to improve the quality of life for patients while at the same time saving the health system billions of dollars each year. The Biosimilars Council, a division of AAM, works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products.
To recognize the potential of biosimilars, it is essential to first understand that biologic medicines are often the only treatments available for serious illnesses, like cancer or genetic disorders. However, this type of medication comes at steep expense to patients, taxpayers and insurers. FDA-approved biosimilars are safe, effective alternative versions of existing biologic medicines.
AAM is working with our partners to ensure that the right policies are in place to nurture a robust marketplace. Data from Europe, where biosimilars have been available since 2006, show that the use of lifesaving biologic treatments has grown significantly as lower-cost biosimilars have become available and given patients an affordable option to expensive brand products.
The Biosimilars Council is a division of the Association for Accessible Medicines, an organization dedicated to improving access to safe, quality, effective medicine. The Biosimilars Council works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products. Since its establishment in 2015, the Biosimilars Council has focused on issues facing the biopharmaceutical industry, including education, patient access, the regulatory and reimbursement environment, federal and state legislation and legal affairs.
- Biosimilars Council
- Biosimilars Advocacy and Action Center
- Biosimilars Patient Resource Center
- Biosimilars Council: Medical Professional Learning Track
- Biosimilars Council: Policy Maker Learning Track
- Biosimilars Council: Insurer Learning Track